logo

Sage Therapeutics, Inc. (SAGE)



Trade SAGE now with
  Date
  Headline
7/3/2019 6:34:41 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4/3/2019 6:34:17 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/21/2019 9:10:04 AM Ligand To Receive $3 Mln Milestone Payment As Result Of FDA Approval Of Sage Therapeutics’ ZULRESSOTM Injection
2/19/2019 6:47:06 AM Sage Therapeutics q4 Net Loss $158.4 Mln Or $3.38/Shr Vs Loss $69.4 Mln Or $1.75/Shr Last Year
2/7/2019 6:33:42 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/23/2019 7:05:32 AM Sage Therapeutics Appoints Elizabeth Barrett And George Golumbeski To Board
1/7/2019 7:09:31 AM Sage Therapeutics To Provide Update On Key 2019 Initiatives
1/7/2019 6:03:18 AM Sage Therapeutics Says SAGE-217 Meets Primary, Secondary Endpoints In Phase 3 Clinical Trial In Postpartum Depression
1/4/2019 6:30:38 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/20/2018 7:34:41 AM Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO Injection
11/6/2018 6:37:52 AM Sage Therapeutics Q3 Net Loss $122.9 Mln Vs Net Loss $73.7 Mln Last Year
11/5/2018 6:34:34 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/2/2018 7:18:32 AM Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO Injection
9/6/2018 6:36:16 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  
 
>